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Abstract
Endometriosis, a disease of reproductive age women, is a major cause of infertility, menstrual disorders and pelvic pain.
Little is known about its etiopathology, but chronic pelvic inflammation is a common feature in affected women. Beside
symptomatic treatment of endometriosis-associated pain, only two main suboptimal therapeutic approaches (hormonal
and invasive surgery) are generally recommended to patients and no specific targeted treatment is available. Our studies led
to the detection of a marked increase in the expression of macrophage migration inhibitory factor (MIF) in the eutopic
endometrium, the peripheral blood and the peritoneal fluid of women with endometriosis, and in early, vascularized and
active endometriotic lesions. Herein, we developed a treatment model of endometriosis, where human endometrial tissue
was first allowed to implant into the peritoneal cavity of nude mice, to assess in vivo the effect of a specific antagonist of
MIF (ISO-1) on the progression of endometriosis and evaluate its efficacy as a potential therapeutic tool. Administration of
ISO-1 led to a significant decline of the number, size and in situ dissemination of endometriotic lesions. We further showed
that ISO-1 may act by significantly inhibiting cell adhesion, tissue remodeling, angiogenesis and inflammation as well as by
altering the balance of pro- and anti-apoptotic factors. Actually, mice treatment with ISO-1 significantly reduced the
expression of cell adhesion receptors av and ß3 integrins (P,0.05), matrix metalloproteinases (MMP) 2 and 9 (P,0.05),
vascular endothelial cell growth factor (VEGF) (P,0.01), interleukin 8 (IL8) (P,0.05), cyclooxygenease (COX)2 (P,0.001) and
the anti-apoptotic protein Bcl2 (P,0.01), but significantly induced the expression of Bax (P,0.05), a potent pro-apoptotic
protein. These data provide evidence that specific inhibition of MIF alters endometriotic tissue growth and progression in
vivo and may represent a promising potential therapeutic avenue.
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Introduction
Endometriosis, a gynecological complication characterized by
extra-uterine localization of endometrial tissue, mainly in on pelvic
organs, affects 5 to 10% of reproduction age women [1]. Its
diagnosis remains very difficult, but a positive diagnosis is
generally associated with pelvic pain (60%), dysmenorrhea
(30%), dyspareunia (36%) and infertility (50%) [2]. Endometriosis
is hormone-dependent and genetic and environmental factors may
play a role in its development [3,4,5]. Beside symptomatic
treatment of endometriosis-associated pain, only two main
suboptimall therapeutic approaches in particular hormonal and
invasive surgical [6,7] are generally recommended to patients and
no specific targeted treatment is available. Chronic pelvic in-
flammation is a hallmark of endometriosis pathophysiology.
Evidence available to date indicates that immune and inflamma-
tory factors, whether they are released by immune or peritoneal,
endometrial and endometriotic cells, may play a critical role in the
ectopic survival, implantation and growth of endometrial tissue
[1,8,9,10,11]. Curiously, instead of eliminating misplaced endo-
metrial cells, immune cells like macrophages are more activated in
women with endometriosis and release factors that may exacerbate
inflammation and facilitate endometrial tissue adhesion, invasion
and growth within the host tissue [9,12,13,14,15,16].
Our previous studies showed a marked increase in macrophage
migration inhibitory factor (MIF) in eutopic endometrial tissue of
women with endometriosis, which varied according to the disease’s
stage and major symptoms [17]. We further found a significant
elevation in the circulating [18] and local peritoneal [11] levels of
MIF and an increased expression of this factor in early,
vascularized and most active endometriotic lesions [19]. MIF
was also overproduced by activated peritoneal macrophages of
women with endometriosis. The available literature supports our
findings [12,20,21,22]. Initially, MIF was defined as a cytokine
that inhibits macrophage migration [23]. But today, MIF is known
as an important regulator of the host immune system that
promotes the pro-inflammatory functions of immune cells [24,25].
In addition, MIF has been shown to be implicated in angiogenesis,
tumorigenesis, as well as in many inflammatory and autoimmune
diseases [26,27,28,29,30,31,32,33,34,35,36]. Our previous studies
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and favor angiogenesis in vitro and in vivo [28,29,31,37]. Based on
these findings, we hypothesize that MIF may and via different
direct and indirect mechanisms play an important role in the
development of endometriosis. The present study was therefore
designed to evaluate the efficacy of a specific MIF inhibitor called
ISO-1 as a potential treatment for endometriosis using an in vivo
model of endometriosis. ISO-1 or (S,R) 3-(4-hydroxyphenyl)-4,5-
dihydro-5-isoxazole acetic methyl ester) is defined as a highly
specific inhibitor to the catalytic site of MIF [38]. Our data showed
that treatment with ISO-1 leads to a significant regression of
established ectopic endometrial implants and a marked down-
regulation of angiogenic, tissue remodeling and survival factors,
and may represent a promising approach for the treatment of
peritoneal endometriosis.
Materials and Methods
Animals
Five-seven weeks old female athymic nude mice (Harlan, USA)
were used in this investigation. The animals were housed (two/
cage) under laminar-flow (HEPA)-filtered hoods in rooms main-
tained at 28uC with a 12:12-hour light-dark cycle. Housing
material, food and water were sterilized before use. This study was
approved by the ‘‘Comite ´ de protection des animaux du CHUQ’’
(permit ID: 2009068-3). In vivo experiments were performed
according to the Canadian committee of animal’s protection
(CPA) rules.
Endometrial biopsies were obtained from four patients (mean
age 6 SD, 41.565.2 years) undergoing surgical explorative
laparoscopy or hysterectomy for fibroma, myoma, bleeding and
infertility problems. These patients signed an informed consent
and accepted to participate to this research project, which was
approved by Saint-Franc ¸ois d’Assise Hospital ethics committee on
human research (Laval University, Que ´bec, Canada) (project ID:
5-00-12-07). Included women did not have endometriosis and
were not receiving anti-inflammatory or hormonal medication for
at least 3 months before surgery. Biopsies were collected using
a Pipelle de Cornier (Prodimed, Neuilly-en-Tchelle, France)
during the proliferative phase (d2-d13) of the menstrual cycle.
The menstrual cycle phase was confirmed by histology [39].
Tissue samples were placed in cold sterile Hank’s balanced salt
solution containing 100 IU/ml penicillin, 100 mg/ml streptomy-
cin and 0.25 mg/ml amphotericin B (Invitrogen Life Technolo-
gies, Burlington, ON, Canada) and immediately transported to the
laboratory. A small sample of each tissue was fixed at 4uC in 10%
formalin and processed to paraffin for histological analysis and the
remaining tissue was immediately used for in vivo studies.
In Vivo Model of Endometriosis
Endometrial tissue was washed twice with in phosphate buffered
saline (PBS), dissected into thirteen small cubes (,161m m
3) per
mouse and labeled with carboxyfluorescein diacetate, succinimidyl
ester (CFDA-SE) (8.10
26 M) (Invitrogen, Burlington, ON, Ca-
nada) during 20 min at room temperature. Tissue fragments were
then washed twice in PBS and examined under a fluorescence
stereomicroscope to confirm labeling. Animals were given
buprenorphine (1.68g/mouse) by intradermal injection for anal-
gesia, then anesthetized with a mixture of oxygen (1.5 l) and
isofluraneH (3–4%) (Abbot Laboratories, Saint-Laurent, Quebec,
Canada). The model mimics endometriosis in nude mice by
inoculating endometrial tissue into the peritoneal cavity. To access
the peritoneal cavity, we made a small incision (1 cm) in the
cutaneous tissue and the underneath peritoneal tissue. Thirteen
CFDA-labelled endometrial tissue fragments in 0.1 ml PBS were
then injected into the peritoneal cavity through this opening using
micropipette as shown in Figure 1A. The peritoneal incision was
sutured with coated NB (polyglactin 910) sutures (Ethicon Johnson
& Johnson, Ontario, Canada) and the cutaneous incision was
closed with MikRon autoclip 9 mm (Clay Adam Brand, Sparks,
USA). Inoculated mice were monitored daily for comfort, survival
and body weight until day 12 post-inoculation. Beginning on day
12, animals received a daily intra-peritoneal injection (100 ml) of
sterile PBS used as vehicle (control group, n=8) or PBS containing
ISO-1 (4 mg/kg) (n=8) [38]. Injections were performed until day
25 post-inoculation. Animals were monitored daily for weight and
survival rate (Figure 1A). Fourteen days post-treatment, animals
were anesthetized with isoflurane/O2 (3–4%), then euthanized in
an atmosphere saturated by CO2 (10 l/min) and the abdominal
cavity of each mouse was explored using a fluorescence stereomi-
croscope for in situ identification, localization, enumeration and
measure of endometriotic lesions using a caliper precision
instrument (Figure 1B). Lesions were photographed in situ using
a color CCD HD camera (DAGE-MTI, Michigan City, IN, USA).
Finally, lesions were removed and stored at 280uC for molecular
analysis or fixed in cold formaldehyde (10% in PBS) and
embedded in paraffin for histological studies.
RNA extraction and quantitative real-time polymerase chain
reaction (qRT-PCR).
Figure 1. Schematic illustration of the experimental design. A)
Human endometrial tissue was inoculated into the peritoneal cavity of
mice using a micropipette and left for 12 days before starting
treatment. ISO-1 was then intra-peritoneally administered on a daily
basis for 14 consecutive days before euthanizing the animals. B) Size of
injected endometrial fragments.
doi:10.1371/journal.pone.0037264.g001
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reported [28], RNA was extracted separately from each surface
and deep implant. qRT-PCR was performed using an ABI 7000
Thermal Cycler (Applied Biosystems, Foster City, CA). Each
standard PCR reaction contained 2 ml reverse transcriptase (RT)
product, 0.5 ml of each primer (final concentration, 0.1 mM),
12.5 ml SYBR Green PCR Master Mix (Invitrogen) consisting of
Taq DNA polymerase reaction buffer, deoxynucleotide triphos-
phate mix, SYBR green I, MgCl2, and Taq DNA polymerase. The
conditions of reaction and the listing of primers are reported in the
Table 1. Primers were designed with Primer Premier 5 software to
cross intron-exon boundaries. All samples were tested in duplicate
and for each reaction; negative controls without RNA and without
reverse transcriptase were added.
Histological Analysis
Four-mm sections of tissue were rehydrated and stained with
hematoxylin and eosin (H & E) according to a standard procedure
[40].
Statistical Analysis
Statistical tests used in this study were the Kruskal-Wallis for the
analysis of the evolution of the body weight during tissue
inoculation and treatment, the Mann-Whitney for the number
and volume of lesions per mouse and qRT-PCR data, which
followed non-parametric distributions, and student t-test for the
number and volume of lesions per tissue, which were normally
distributed. Results were expressed as mean 6 SEM. All statistical
analyses were performed using GraphPad Prism software (San
Diego, CA, USA). Differences were considered as statistically
significant for P,0.05.
Results
Establishment of Experimentally-induced Endometriosis
In this model, human endometrial tissue was allowed to
implant and establish in nude mice before starting treatment.
Histological analysis of implants prior to any treatment showed
a well-preserved endometrial structure comparable to that of
initial endometrial tissue, with glands surrounded by stroma,
and distinguishable from the underneath murine host tissue.
However, endometriotic lesions showed more dilated glands,
which might be due to accumulation of glandular cell secretions
(Figure 2, A and B). Induction of endometriosis had no
perceptible effect on the health of these animals. All mice
survived (Figure 2C) and no body weight difference between
tissue-inoculated and control mice was observed (Figure 2E).
The use of CFDA-SE fluorochrome allowed us to easily identify
endometriotic lesions, and 6062.5% of endometrial tissues
initially injected per mouse were collected.
Impact of the Treatment of Mice with ISO-1
Survival and weight of animals. All mice survived after
treatment with 4 mg/kg ISO-1 (Figure 2D). On the other hand,
five days post-treatment, animals exposed to vehicle showed some
body weight loss estimated at 6.061.8%, which, however, was not
significant as compared to the initial weight and recovered at the
end of treatment. Animals exposed to ISO-1 showed no significant
weight loss of gain (Figure 2F).
Number, size and histology of lesions. Fourteen days
post-treatment, mice were euthanized and macroscopic explora-
tion was immediately performed using a stereomicroscope
equipped with a fluorescein isothiocyanate (FITC) filter. On gross
morphological examination, mice treated with ISO-1 had
a minimal sign of disease compared with control mice treated
with the vehicle alone, which clearly had more, larger and well-
defined endometriotic lesions (Figure 3A). Furthermore, deep
infiltrating endometriotic lesions, which were only observable by
fluorescence, were identified. These lesions were smaller in mice
treated with ISO-1 than in control mice (Figure 3B). Histological
evaluation of the harvested lesions showed a human endometrial
tissue, which, in control mice, closely adhered to the host mouse
tissue and exhibited many well-defined, secretory and active
endometrial glands (Figure 3C). However, in mice treated with
ISO-1, endometrial tissue was detached from the host tissue and
showed essentially small, degenerate and most probably inactive
glandular structures (Figure 3D).
Tissue invasiveness and dissemination. Analysis of har-
vested lesions relative to the implantation site showed several
invaded organs and tissues in control mice, such as the peritoneum
(52%), fat tissue (30%), the liver (8%), the bowel (6%), the colon
(2%) and the kidney (2%), while in mice treated with ISO-1,
endometrial implants were only recovered in the peritoneum
(48%) and fat tissue (52%) (Figure 4, A and B). Statistical analysis
showed a significant decrease in lesion number and volume in
ISO-1-treated mice compared with vehicle-treated controls
(P,0.05 and P,0.01, respectively) (Figure 4, C and D).
Furthermore, in mice treated with ISO-1, lesion number was
significantly reduced in the peritoneum (P,0.05), while lesion size
was reduced both in the peritoneum and fat tissue (P,0.05)
(Figure 4E-H).
In order for the endometrial tissue to implant and growth into
the ectopic sites, a complex network of biological processes would
Table 1. List of PCR primers.
Gene Primers Tm
GeneBank
accession #
Bax F-TCAACTGGGGCCGGGTTGTC 60uC NM_004324.3
R-CCTGGTCTTGGATCCAGCC
Bcl2 F-ACATGCTCGCCCAGCCAC 60uC NM_000657.2
R-TGCACATGGGGCATCTTGG
COX2 F-TCAACTGGGGCCGGGTTGTC 60uC NM_000963
R-AAAACTGATGCGTGAAGTGCTG
GAPDH F- CAGGGCTGCTTTTAACTCTGG 60uC NM_002046.3
R-TGGGTGGAATCATATTGGAACA
IL8 F-TGGCAGCCTTCCTGATTT 60uC NM_000584.2
R-AGGTTTGGAGTATGTCTTTATGC
Integrin av F-GGAGCAATTCGACGAGCACT 60uC NM_001144999.1
R-TTCATCCCGCAGATACGCTA
Integrin b3 F-TGACGAAAATACCTGCAACCG 60uC NM_000212.2
R-GCATCCTTGCCAGTGTCC
MMP2 F-TTGACGGTAAGGACGGACTC 60uC NM_001127891.1
R-ACTTGCAGTACTCCCCATCG
MMP-9 F-TTGACAGCGACAAGAAGTGG 60uC NM_004994.2
R-CCCTCAGTGAAGCGGTACAT
TIMP1 F-AAGGCTCTGAAAAGGGCTTC 60uC NM_003254.2
R-GAAAGATGGGAGTGGGAACA
VEGF F-GCTCTACCTCCACCATGCCA 60uC NM_001171630.1
R-CACCACTTCGTGATGATTCTG
doi:10.1371/journal.pone.0037264.t001
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angiogenesis. To investigate the molecular pathways that may
underlie the inhibitory effect of ISO-1 treatment on ectopic
endometrial tissue growth and dissemination observed in vivo,w e
further assessed the expression of main apoptosis, adhesion,
proteolysis and angiogenesis mediators found to be significantly
dysregulated in human endometriotic lesions. Data displayed in
Figure 5, A and B, shows a significant effect of ISO-1 on Bax and
Bcl2. In fact, while the expression Bax, a major pro-apoptotic
factor, was upregulated in lesions harvested from ISO-1-treated
mice (P,0.05), the expression of Bcl2, which is known for its anti-
apoptotic properties, was significantly downregulated (P,0.01).
ISO-1 treatment also led to a significant inhibition of the
expression of adhesion receptors integrins av and b3i n
endometrial implants (P , 0.05) (Figure 5, C and D).
We then analyzed the expression of MMP2 and MMP9, which
have been found to be up-regulated in active endometriotic lesions
and may contribute to the invasive capacity of endometrial
implants as well as to angiogenesis [41,42,43]. As shown in
Figure 6, A and B, treatment of mice with ISO-1 had a significant
downregulatory effect on the expression of MMP2 and MMP9
(P,0.05). However, no statistically significant effect on TIMP1,
a natural tissue inhibitor of MMPs, was noted (Figure 6C).
Furthermore, treatment with ISO-1 significantly inhibited the
expression of vascular endothelial cell growth factor (VEGF),
a major angiogenic factor, (P,0.01) (Figure 6D) and that of
Figure 2. Histological examination of human endometrial implants in nude mice two weeks after inoculation of endometrial tissue.
A) Initial endometrial tissue before inoculation into mice. B) Endometrial implant 12 days following tissue inoculation showing epithelial glands (EG)
surrounded by endometrial stromal cells (S) and mouse tissue (MT). Hematoxylin-eosin staining; scale bar, 20 mm. C and D) Effect of endometrial
tissue inoculation and treatment with ISO-1 on the survival rate of animals. E and F) Effect of endometrial tissue inoculation and treatment with ISO-1
on the body weight of animals. The Figure summarizes results obtained from 7 mice treated with ISO-1 (4 mg/kg) and 8 control mice treated with
vehicle.
doi:10.1371/journal.pone.0037264.g002
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inflammation, angiogenesis and tissue remodeling
[28,44,45,46,47] (P,0.001 and P,0.05, respectively) (Figure 6,
E and F).
Discussion
It is well documented today that endometriosis is often
associated with chronic pelvic inflammation. Significant im-
muno-inflammatory changes have been observed in the eutopic
endometrium of women with endometriosis, but also in the
peritoneal cavity of patients where the disease frequently develops,
and within and around endometriotic lesions [1,8,9,10,11,48]
These changes may contribute to the development of the disease.
For instance, immune cells, particularly macrophages, which are
the main immune cell types found in the peritoneal fluid, seem to
be less phagocytotic and despite their increased number and
activation status, they lack the capability of eliminating endome-
trial debris [9,49]. These cells resist apoptosis and produce
proinflammatory, angiogenic, growth and tissue remodeling
factors, which may contribute to the ectopic growth of endometrial
tissue [12,13,14,15,16,50]. Known for its capability to inhibit
macrophage migration, MIF activates macrophages and may
therefore play a role in retaining these cells into the inflammatory
sites [23,51]. Our previous studies showed an increased secretion
of MIF by peritoneal macrophages of women with endometriosis
[12] and further revealed an increased expression of this factor in
eutopic endometrium and initial, active and vascularized en-
dometriotic lesions [17]. Moreover, either local peritoneal fluid or
systemic circulating levels of MIF were found to be higher in
women with endometriosis and appeared to depend on the
disease’s stage and major clinical symptoms (pain and infertility)
[11,17,18,19]. These observations were confirmed by other studies
[20,52]. Interestingly, according to Seeber et al, the association of
Figure 3. Stereomicroscopic observation and histological examination of endometrial implants. A and B) Surface and deep implants,
respectively, were observed at sacrifice by fluorescence stereomicroscopy in mice treated with vehicle (a, b, c) or ISO-1 (4 mg/kg) (d, e, f). Implants, as
observed by optic light (a, d) or epi-fluorescence (b, e). Merged images are shown (c, f). C and D) Histological examination of endometrial implants
from control mice treated with vehicle or 4 mg/kg ISO-1, respectively. EG, endometrial gland; HT, human tissue; MT, mouse tissue; scale bar, 10 mm.
doi:10.1371/journal.pone.0037264.g003
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1 (MCP1) and leptin, can diagnose endometriosis in 48% of
patients with a specificity equal to 93% [53]. Taken together, these
findings strongly suggest that targeting MIF, using specific
inhibitors, may represent an interesting strategy for treating
endometriosis.
The present study used an in vivo model of experimentally
induced endometriosis, where human endometrial tissue was
allowed to implant and grow prior to any treatment. Both
surface and deep endometrial implants were found, and the
implanted tissue displayed endometrial stromal and glandular
structures similar to those of the initial tissue. Implants were
precisely identified, measured and harvested as they were
labeled with a fluorescent marker before being inoculated into
animals. Our data showed that ISO-1, a specific inhibitor of
MIF [54], inhibits human endometrial tissue growth in the
Figure 4. Effect of ISO-1 on endometrial implant number, volume and dissemination. Endometrial implants were localized using
fluorescence stereomicroscopy, then counted and measured in situ. A and B) Schematic representation of colonized mouse organs or tissues (%).
C and D) number and volume of lesions/mouse following treatment with vehicle (control) or 4 mg/kg ISO-1. E and F) Number and volume of lesions
according the implantation site in mice treated with vehicle (control). G and H) Number and volume of lesions according the implantation site in mice
treated with or 4 mg/kg ISO-1. Results were from 8 control mice treated with vehicle and 7 mice treated with ISO-1 (4 mg/kg). Data are mean 6 SEM.
*, **, P,0.05 and P,0.01, respectively, as compared to the control group.
doi:10.1371/journal.pone.0037264.g004
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number and extent of dissemination. ISO-1 treatment disrupted
endometrial tissue structures and gland secretory activity,
reduced tissue invasion and growth into the main colonized
sites, such as the peritoneum and fat tissue, and abolished its
development in the liver, the bowel, the colon and the kidney.
Molecular analyses further showed that ISO-1 acted on several
biological pathways closely associated with the pathogenesis of
endometriosis. Actually, ISO-1 appeared to downregulate the
expression of Bcl2 and to up-regulate in parallel the expression
of Bax, which, respectively, favor cell survival and apoptosis
[55]. Also, ISO-1 treatment significantly downregulated the
expression of the proteolytic enzymes MMP2 and MMP9, but
had no significant effect on their natural specific tissue inhibitor
TIMP1 [42,43]. These data suggest that ISO-1 treatment acts
by altering the balance of pro- and anti-apoptotic factors in
endometriotic implants and that of pro- and anti-proteolysis
molecules. Such a dual complementary effect may, in combi-
nation with the significant inhibition of main adhesion,
angiogenic and proinflammatory mediators such as integrins
av and b3, VEGF, IL8 and COX2, deeply affect endometrial
tissue survival in the ectopic sites and reduce its growth,
invasiveness and dissemination.
The development of endometriotic lesions requires critical steps
including the capacity of the migrating endometrial tissue to
survive and resist apoptosis, attach to and invade the host tissue,
proliferate and activate the host angiogenic responses. This is
supported by the detection of numerous alterations in the
apoptotic pathways, including a significant up-regulation of the
anti-apoptotic molecule Bcl2 and a significant down-regulation of
the pro-apoptotic factor Bax [55], and an increased expression of
integrin receptors av and b3 which are also markers of active
neovascularization and play an important role in cell adhesion to
the extracellular matrix (ECM) [56,57]. Other studies showed that
MMPs, which are required for ECM degradation during tissue
invasion [9,58] and crucial for sprouting of capillaries from pre-
existing vessels, were over-expressed in active endometriotic
lesions [41,42,43]. This was also reported for VEGF, IL8 and
COX2, which are key mediators of angiogenesis, cell proliferation
and inflammation [28,44,45,46,47,59].
MIF is now known for being a multifunctional factor with a wide
spectrum of effects and cell targets. MIF plays an essential role in
Figure 5. Real time PCR analysis of the expression of Bax, Bcl2, integrin av and integrin b3 in endometriotic lesions. Lesions were
harvested from mice treated with vehicle (control) or 4 mg/kg ISO-1. mRNA levels were normalized to that of the house-keeping gene GAPDH.
Results were from 8 control mice treated with vehicle and 7 mice treated with ISO-1. Data are mean 6 SEM. *, **, P,0.05 and P,0.01, respectively, as
compared to the control group.
doi:10.1371/journal.pone.0037264.g005
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[26,27,28,29,30,31,34,35]. Recent data from the literature and
our laboratory showed an important role for MIF in cell
proliferation [60,61], inhibition of apoptosis [62,63,64], stimula-
tion of metalloproteinases [65,66] and induction of angiogenesis
[30,31,67,68,69,70]. MIF stimulates COX2 expression in ectopic
endometrial cells and elicit a pro-angiogenic and pro-inflamma-
tory phenotype [28,37], thereby potentiating their capability to
stimulate the host angiogenic response and exacerbate the
immuno-inflammatory reaction occurring in the implantation site.
ISO-1 binds to the enzymatic active site of MIF, thereby
inhibiting its effects on target cells [38,71]. MIF has two receptors
CD74 and CD44, and the available literature including ours
indicates that MIF activates cells via CD74 and triggers the
activation of p38 and ERK 1, 2 MAPK signaling pathways
[28,37,72]. Our previous studies with endometriotic cells showed
Figure 6. Real time PCR analysis of the expression of MMP2, MMP9, TIMP1, VEGF, COX2 and IL8 in endometriotic lesions. Lesions
harvested from mice treated with vehicle (control) or 4 mg/kg ISO-1. mRNA levels were normalized to that of the house-keeping gene GAPDH.
Results were from 8 control mice and 7 mice treated with ISO-1. Data are mean 6 SEM. *, **, ***, P,0.05, P,0.01 and P,0.001, respectively, as
compared to the control group.
doi:10.1371/journal.pone.0037264.g006
ISO-1 as a Potential Treatment of Endometriosis
PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e37264the involvement of p38 and ERK pathways in VEGF mRNA
synthesis and protein secretion and the inhibitory effect of ISO-
1[37]. We also showed the involvement of these pathways in MIF-
induced COX2 expression (mRNA and protein) and inhibition by
ISO-1 [28]. Research is underway to assess whether these
pathways are also involved in the expression of the MIF-induced
or -inhibited factors shown in the present in vivo work, using
primary endometriotic cells, but also endometrial cells from
women with and without endometriosis, either at the transcrip-
tional or the post-transcriptional level.
Nude mice are deficient in T cells, but still have the capability of
mounting a partial immune response because of functional natural
killer cells and macrophages [73], which may be activated by
exogenous endometrial tissue. It was also shown that CD45
positive leukocytes are recruited into endometriotic lesions in nude
mice [74]. However, further studies will also be necessary to
evaluate the effects of ISO-1 with endometrial tissue from women
with endometriosis since it differs from normal endometrium and
showed an increased expression of MIF [17].
Several previous studies showed the benefit of targeting MIF for
treating inflammatory diseases such as asthma, sepsis, [32], and
viral infection [33]. Therefore, our data demonstrating for the first
time that ISO-1, a specific antagonist of MIF, effectively interferes
with the growth and progression of established endometriosis
lesions in vivo, supports a potential therapeutic interest for this
molecule. The current medical treatment of the disease is mainly
based on the induction of a hypoestrogenic state, which, however,
is associated with serious side effects and a high recurrence, and
there is a crucial need for non-steroid targeted treatment of
endometriosis.
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